The presentation to the webcast – top-line data HORIZON

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients. On June 16 at 10:00 (CET), CEO Jakob Lindberg comments on the top-line results. Follow the webcast via the link below.
The presentation is available below.